Mylan’s EpiPen price hike was a scheme to stifle competition, rival claims

Re:Mylan’s EpiPen price hike was a scheme to stifle competit... by maxerickson on Wednesday April 26, 2017 @10:12AM (#14203092)

Mylan bought it after someone came up with a minor improvement to the needle cap and it could be marketed under a patent.

The ridiculous price has little to do with the original inventor.

A not stupid regulatory system would evaluate the value of the improvement to the market (likely hugely negative in this case). The idea wouldn't be to deny the company the right to the patent, it would be to deny regulatory approval for the patented version of the device.

(the argument being that decreased access to the patented device costs more than the benefit provided by the minor safety improvements it offers).

[ Parent | on HN ]

Re:Mylan’s EpiPen price hike was a scheme to stifle competit... by golergka on Wednesday April 26, 2017 @10:15AM (#14203116)

When you got a regulatory system that evaluates value, you got a complex, corruption and bug prone system.

I'd take my systems stupid and simple, please.

[ Parent | on HN ]

Re:Mylan’s EpiPen price hike was a scheme to stifle competit... by maxerickson on Wednesday April 26, 2017 @10:17AM (#14203137)

A simple implementation would force them to market the new pen under a different name.

They would of course argue that this confuses the marketplace. But they are sitting there exploiting the confused marketplace, so not much of an argument to be made along those lines.

[ Parent | on HN ]